All In Biotech

Free tool

FAERS Monitor: Zydelig

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206545 or its brand name (Zydelig, Idelalisib). Reports on generic versions are filed under their own applications.

Reports

7,040

Serious

6,806

97% of reports

Hospitalization

2,991

Death reported

1,612

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression1,225
  • death802
  • diarrhoea771
  • off label use573
  • pneumonia437
  • pyrexia375
  • drug ineffective318
  • fatigue301
  • dehydration244
  • neutropenia224
  • dyspnoea220
  • colitis203
  • asthenia202
  • pneumonitis200
  • rash182

Reports by year received

View as table
YearReports
20134
2014253
20151,404
20161,357
20171,226
2018980
2019586
2020377
2021257
2022197
2023182
2024113
202594
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal1,22531.229.735,662
pneumonitisSignal20022.119.33,983
colitisSignal20316.114.02,845
dehydrationSignal2445.54.8892
neutropeniaSignal2244.94.3701
pneumoniaSignal4374.03.71,009
diarrhoeaSignal7713.63.31,468
pyrexiaSignal3753.22.9588
deathSignal8022.82.6952
off label use5732.01.8278
asthenia2021.61.446
rash1821.21.19
dyspnoea2201.21.05
fatigue3011.21.06
drug ineffective3180.70.636

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.